ARVN / Arvinas, Inc. - Depositi SEC, Relazione annuale, dichiarazione di delega

Exhibit 99.1 Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer – Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significan

vepdegestrantndaacceptan Exhibit 99.1 Arvinas Announces FDA Acceptance of the New Drug Application for Vepdegestrant for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer – Filing based on pivotal Phase 3 VERITAC-2 clinical trial demonstrating statistically significant and clinically meaningful improvement in median progression-free survival versus fulvestrant – – Vepdegestrant is the first

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Consulting Agreement, dated June 6, 2025, by and between Arvinas Operations, Inc. and Ian Taylor, Ph.D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data f

Exhibit 99.1 Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update – Submitted New Drug Application for vepdegestrant for the treatment of ESR1m, ER+/HER2- advanced or metastatic breast cancer – – Presented ARV-102 SAD and MAD data from the Phase 1 clinical trial in healthy volunteers; initiated dosing in patients with Parkinson’s disease – – Presented preclinical dat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 Arvinas, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 9, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Arvinas, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 25, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Arvinas, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

Exhibit 99.1 Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress – ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angi

ehadatarelease61325 Exhibit 99.1 Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress – ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In combination with small molecule inhibitors, AR

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 Arvinas, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

Arvinas Announces Submission of New Drug Application to U.S. FDA for Vepdegestrant for Patients with ESR1-Mutated ER+/HER2- Advanced or Metastatic Breast Cancer – This submission is supported by the pivotal Phase 3 VERITAC-2 clinical trial, results o

exhibit991-vepdegestrant Arvinas Announces Submission of New Drug Application to U.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2025 Arvinas, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

Exhibit 99.1 May 31, 2025 Pfizer Media Contact: Pfizer Investor Contact: +1 (212) 733-1225 [email protected] +1 (212) 733-4848 [email protected] Arvinas Media Contact: Arvinas Investor Contact: Kirsten Owens +1 (203) 584-0307 Kirsten.Owens@

veritac2asco2025xpressr Exhibit 99.1 May 31, 2025 Pfizer Media Contact: Pfizer Investor Contact: +1 (212) 733-1225 [email protected] +1 (212) 733-4848 [email protected] Arvinas Media Contact: Arvinas Investor Contact: Kirsten Owens +1 (203) 584-0307 [email protected] Jeff Boyle +1 (347) 247-5089 [email protected] Arvinas and Pfizer's Vepdegestrant Significantly Improves Prog

Financial Statements and Exhibits, Costs Associated with Exit or Disposal Activities, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 30, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first n

Exhibit 99.1 Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update – Reported positive topline results from the Phase 3 VERITAC-2 trial that support global regulatory filings – – Presented first-in-human data for the Company’s first neuroscience program with ARV-102 showing blood-brain barrier penetration and central and peripheral LRRK2 degradation – – Announced the r

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S

Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting – ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, i

Exhibit 99.1 Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting – ARV-393 demonstrated strong synergistic antitumor activity, including complete regressions, in combination with standard-of-care chemotherapy, biologics, and select investigational oral small molecule inhibitors – – Findings suppo

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 28, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 Arvinas, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 4, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation – Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brai

Exhibit 99.1 Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation – Data demonstrate that ARV-102 was well tolerated, orally bioavailable, and brain-penetrant; ARV-102 achieved central and peripheral LRRK2 reduction indicating substantial LRRK2 protein degradation in healthy voluntee

Exhibit 99.1 For Immediate Release March 11, 2025 Media Contact: Investor Contact: +1 (212) 733-1225 [email protected] +1 (212) 733-4848 [email protected] Arvinas Media Contact: Arvinas Investor Contact: Kirsten Owens +1 (203) 586-0307 Kirs

EX-99.1 2 ex991-finalveritacx2tlr.htm EX-99.1 Exhibit 99.1 For Immediate Release March 11, 2025 Media Contact: Investor Contact: +1 (212) 733-1225 [email protected] +1 (212) 733-4848 [email protected] Arvinas Media Contact: Arvinas Investor Contact: Kirsten Owens +1 (203) 586-0307 [email protected] Jeff Boyle +1 (347) 247-5089 [email protected] Arvinas and Pfizer Announce Po

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

LIMITED POWER OF ATTORNEY FOR FORM 144 REPORTING OBLIGATIONS

LIMITED POWER OF ATTORNEY FOR FORM 144 REPORTING OBLIGATIONS With respect to holdings of and transactions in securities issued by Arvinas, Inc.

LIMITED POWER OF ATTORNEY FOR FORM 144 REPORTING OBLIGATIONS

LIMITED POWER OF ATTORNEY FOR FORM 144 REPORTING OBLIGATIONS With respect to holdings of and transactions in securities issued by Arvinas, Inc.

LIMITED POWER OF ATTORNEY FOR FORM 144 REPORTING OBLIGATIONS

LIMITED POWER OF ATTORNEY FOR FORM 144 REPORTING OBLIGATIONS With respect to holdings of and transactions in securities issued by Arvinas, Inc.

JOINT FILING AGREEMENT

EX-99.1 2 tm256231d1ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the initial Statement on Schedule 13G filed on January 30, 2025 (and any amendments thereto (including the amendment filed herewith)), relating to the Shares of Arvinas, Inc. is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securiti

Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated December

Exhibit 10.25

Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated

Exhibit 10.24 [Separately circulated]

Subsidiaries of the Registrant.

Exhibit 21.1 Name of Subsidiary State of Incorporation Arvinas Operations, Inc. Delaware Arvinas Androgen Receptor, Inc. Delaware Arvinas Estrogen Receptor, Inc. Delaware Arvinas Winchester, Inc. Delaware

Third Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated December 13, 2024.

Exhibit 10.30

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-38672 ARVINAS, INC

Insider Trading Policy

1 ARVINAS, INC. Insider Trading Policy Updated Effective November 21, 2024 1. BACKGROUND AND PURPOSE 1.1 Why Have We Adopted This Policy? The federal securities laws prohibit any member of the Board of Directors (each, a “Director” and together, the “Directors”), officer (as defined in Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), an “executive officer”)

Table 1: Newly Registered Securities

Calculation of Filing Fee Tables S-8 ARVINAS, INC. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 3,437,790 $ 17.61 $ 60,539,481.90 0.0001531 $ 9,268.59 Total Offering Am

between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated

Exhibit 10.31

Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated

Exhibit 10.26

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-stu

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update – Announced that topline data from the monotherapy Phase 3 VERITAC-2 trial is anticipated in 1Q25 – – Presented Phase 1b data from the TACTIVE-U sub-study of vepdegestrant in combination with abemaciclib that demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overal

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 11, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

As filed with the Securities and Exchange Commission on February 11, 2025

As filed with the Securities and Exchange Commission on February 11, 2025 Registration No.

Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 15, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Exhibit 99.1 Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update – Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhi

a2025-01x10xjpmcorporate Exhibit 99.1 Arvinas Updates Guidance for First- and Second-Line Phase 3 Combination Trials with Vepdegestrant, Highlights Upcoming Milestones, and Provides Corporate Update – Vepdegestrant to be combined with Pfizer’s novel investigational CDK4 inhibitor atirmociclib in a first-line Phase 3 trial planned to initiate in 2025; a second-line Phase 3 combination trial will co

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2025 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 31, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Exhibit 99.1 Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium – Vepdegestrant in combination with abemaciclib demonstrated enco

Exhibit 99.1 Arvinas and Pfizer Announce Initial Phase 1b Data from the TACTIVE-U Sub-Study of Vepdegestrant in Combination with Abemaciclib at 2024 San Antonio Breast Cancer Symposium – Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate: 62.5%; overall response rate: 26.7%) in patients previously treated with a CDK4/6 inhibitor – – Safe

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

ARVN / Arvinas, Inc. / RTW INVESTMENTS, LP - ARVINAS, INC. Passive Investment

SC 13G/A 1 p24-3264sc13ga.htm ARVINAS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this statement) Check the appropria

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num

Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update – On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combinati

Exhibit 99.1 Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update – On track to report topline data from Phase 3 VERITAC-2 trial in 4Q24 or 1Q25 – – Initial clinical data from Phase 1/2 TACTIVE-U sub-study of abemaciclib in combination with vepdegestrant to be presented at San Antonio Breast Cancer Symposium in December 2024 – – Recently presented new preclinical data

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Arvinas, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Lease Termination Agreement, dated August 15, 2024, by and among Arvinas Operations, Inc. and 101 College Street, LLC

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. [**] [**] [**] [**] [**] [**]

September 11, 2024

September 11, 2024 By Electronic Submission Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.

ARVN / Arvinas, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Arvinas Inc Title of Class of Securities: Common Stock CUSIP Number: 04335A105 Date of Event Which Requires Filing of this Statement: August 30, 2024 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 15, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numb

Amended and Restated License Agreement, by and between Yale University and Arvinas Operations, Inc., dated June 18, 2024.

exhibit106-amendedyaleag Exhibit 10.6 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. ACTIVEUS 204792072v.1 AMENDED AND RESTATED LICENSE AGREEMENT by and between YALE UNIVERSITY And ARVINAS OPERATIONS, INC. Dated JUNE 18

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Asset Purchase Agreement by and among Arvinas, Inc., Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc. and Novartis Pharma AG, dated April 10, 2024

exhibit105-novartisxarvi Exhibit 10.5 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXECUTION VERSION ASSET PURCHASE AGREEMENT between ARVINAS, INC., ARVINAS OPERATIONS, INC., ARVINAS ANDROGEN RECEPTOR, INC. and NOVART

Promotion Letter for Angela Cacace, Ph.D., dated July 8, 2024

exhibit102-cacacepromoti 5 Science Park, New Haven, Connecticut 06511 | T - (203) 535-1456 | F - (203) 691-9457 | www.

Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of ve

Exhibit 99.1 Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update – Completed enrollment in the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting; continued enrollment globally in multiple clinical trials of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting– – Completion of enro

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on

exhibit101-saikemploymen DocuSign Envelope ID: 458EC197-FED0-42A4-9F20-200489BD0A97 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the is made as of June 24, 2024 and RECITALS WHEREAS, the Company desires to employ the Executive as its Chief Financial Officer; WHEREAS, the Executive has agreed to accept such employment on the terms and conditions set forth in this Agreement; NOW, THEREFORE, in consideration of the foregoing and of the respective covenants and agreements of the Parties herein contained, the Parties hereto agree as follows: 1.

License Agreement by and among Arvinas, Inc., Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc. and Novartis Pharma AG, dated April 10, 2024.

exhibit104-novartisxarvi Exhibit 10.4 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. EXECUTION VERSION LICENSE AGREEMENT by and among Arvinas, Inc., Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc. and Novartis

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arvinas, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per

As filed with the Securities and Exchange Commission on June 27, 2024

As filed with the Securities and Exchange Commission on June 27, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2024 Arvinas, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Arvinas, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2024 Arvinas, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 29, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Arvinas, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

Exhibit 99.1 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) – After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), med

Exhibit 99.1 Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) – After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Promotion Letter for Randy Teel, Ph.D., dated April 21, 2024.

Exhibit 10.2

Second Amendment to Lease between 101 College Street, LLC and Arvinas Operations, Inc., dated December 20, 2023

SECON AMENDMENT LEASE nd 0 NOW, THEREFORE, in consideration of the foregoing agreements, ter.

Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the secon

Exhibit 99.1 Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update – Continued enrollment globally in multiple clinical studies of vepdegestrant in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Top-line data readout for VERITAC-2 re

Employment Agreement between the Registrant and Noah Berkowitz, M.D., Ph.D. dated March 18, 2024.

1 ActiveUS 170226715 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made as of March 18, 2024 (the “Effective Date”) by and between Arvinas, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Arvinas, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 10, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

Exhibit 99.1 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer – Arvinas to

Exhibit 99.1 Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer – Arvinas to receive a $150 million upfront payment for the license of ARV-766 and the sale of Arvinas’ preclinical AR-V7 program, with the potential under the Lic

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arvinas, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per

As filed with the Securities and Exchange Commission on March 18, 2024

As filed with the Securities and Exchange Commission on March 18, 2024 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 14, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

Subsidiaries of the Registrant.

Exhibit 21.1 Name of Subsidiary State of Incorporation Arvinas Operations, Inc. Delaware Arvinas Androgen Receptor, Inc. Delaware Arvinas Estrogen Receptor, Inc. Delaware Arvinas Winchester, Inc. Delaware

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Arvinas, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Arvinas, Inc. Dodd-Frank Compensation Recovery Policy

Exhibit 97.1 ARVINAS, INC. Dodd-Frank Compensation Recovery Policy This Compensation Recovery Policy (this “Policy”) is adopted by Arvinas, Inc. (the “Company”) in accordance with Nasdaq Listing Rule 5608 (“Rule 5608”), which implements Rule 10D-1 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (as promulgated pursuant to Section 954 of the Dodd-Frank Wall Street Reform

Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 P

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471) in ER+/HER2- metastatic breast cancer, including the VERITAC-2 Phase 3 trial in the second-line setting and the study lead-in for the VERITAC-3 Phase 3 trial in the first-line setting – – Pending furth

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-38672 ARVINAS, INC

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Arvinas, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

ARVN / Arvinas, Inc. / EcoR1 Capital, LLC Passive Investment

SC 13G/A 1 arvn13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to

ARVN / Arvinas, Inc. / RTW INVESTMENTS, LP - ARVINAS, INC. Passive Investment

SC 13G 1 p24-0730sc13g.htm ARVINAS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2023 (Date of event which requires filing of this statement) Check the appropriate box

ARVN / Arvinas, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0341-arvinasinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Arvinas Inc Title of Class of Securities: Common Stock CUSIP Number: 04335A105 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pur

ARVN / Arvinas, Inc. / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d1098058613g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.2) Arvinas, Inc. (Name of Issuer) common stock, $0.001 par value per share (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arvinas, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per

Form of Inducement Restricted Stock Unit Award Agreement

Exhibit 99.4 ARVINAS, INC. RESTRICTED STOCK UNIT AGREEMENT Inducement Grant Arvinas, Inc. (the “Company”) hereby grants the following restricted stock units. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the “Participant”): Grant Date: Number of Restricted Stock Units (“RSUs”) granted: Vesting Start Date: Vesting Schedule: All vesting is depend

As filed with the Securities and Exchange Commission on January 16, 2024

As filed with the Securities and Exchange Commission on January 16, 2024 Registration No.

Form of Inducement Stock Option Award Agreement

Exhibit 99.3 ARVINAS, INC. NONSTATUTORY STOCK OPTION AGREEMENT Inducement Grant Arvinas, Inc. (the “Company”) hereby grants the following stock option. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of optionee (the “Participant”): Grant Date: Number of shares of the Company’s Common Stock subject to this option (“Shares”): Option exercise price per Share: $

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Arvinas, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2024 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numb

Filing Fee Table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arvinas, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For

As filed with the Securities and Exchange Commission on December 8, 2023

Table of Contents As filed with the Securities and Exchange Commission on December 8, 2023 Registration No.

Vepdegestrant program update - Phase 1b data: combination trial with palbociclib - Development plan update San Antonio Breast Cancer Symposium December 6, 2023 Exhibit 99.2 Safe harbor and forward-looking statements: Arvinas 2 This presentation conta

Vepdegestrant program update - Phase 1b data: combination trial with palbociclib - Development plan update San Antonio Breast Cancer Symposium December 6, 2023 Exhibit 99.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Arvinas, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 5, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program December 5, 2023 – Overall response rate of 42% and median progression-free

Arvinas and Pfizer Announce Interim Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®) and Plans to Expand Vepdegestrant Development Program December 5, 2023 – Overall response rate of 42% and median progression-free survival of 11.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 24, 2023 Arvinas, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 24, 2023 Arvinas, Inc. (Exact Name of Registrant as Specified in Charter) Delaware 001-38672 47-2566120 (State or Other Jurisdiction of Incorporation) (Commission File Number

Form of Pre-Funded Warrant

Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”) OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFEC

Securities Purchase Agreement, dated November 24, 2023, by and among the Company and the other parties thereto

EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is made and entered into as of November 24, 2023 by and among Arvinas, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A attached hereto (each an “Investor” and collectively the “Investors”). RECITALS A. The Company and the Investors are executing and deliv

(incorporated by reference to Exhibit 10.2 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on November 27, 2023).

Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 24, 2023 by and among Arvinas, Inc., a Delaware corporation (the “Company”), and the “Investors” named in that certain Securities Purchase Agreement by and among the Company and the Investors, dated as of November 24, 2023 (the “Purchase Agreement”). Capitalized

Arvinas Announces Oversubscribed $350 Million Private Placement

Exhibit 99.1 Arvinas Announces Oversubscribed $350 Million Private Placement NEW HAVEN, Conn., November 27, 2023 – Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 12,963,5

As filed with the Securities and Exchange Commission on November 7, 2023

Table of Contents As filed with the Securities and Exchange Commission on November 7, 2023 Registration No.

Form of Senior Indenture

Table of Contents Exhibit 4.4 ARVINAS, INC. and Trustee INDENTURE Dated as of SENIOR DEBT SECURITIES Table of Contents CROSS-REFERENCE TABLE1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.0

Form of Subordinated Indenture

Exhibit 4.5 ARVINAS, INC. and Trustee INDENTURE Dated as of SUBORDINATED DEBT SECURITIES CROSS-REFERENCE TABLE 1 Section of Trust Indenture Act of 1939, as amended Section of Indenture 310(a) 6.09 310(b) 6.08 6.10 310(c) Inapplicable 311(a) 6.13 311(b) 6.13 311(c) Inapplicable 312(a) 4.01 4.04 312(b) 4.04(c) 312(c) 4.04(c) 313(a) 4.03 313(b) 4.03 313(c) 4.03 313(d) 4.03 314(a) 4.02 314(b) Inapplic

Form of Senior Note

Exhibit 4.6 Form of Senior Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE OF THE

Filing fee table

Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Arvinas, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry For

Form of Subordinated Note

Exhibit 4.7 Form of Subordinated Note (FACE OF SECURITY) [Each Global Security shall bear substantially the following legend: UNLESS AND UNTIL IT IS EXCHANGED IN WHOLE OR IN PART FOR SECURITIES IN DEFINITIVE REGISTERED FORM, THIS SECURITY MAY NOT BE TRANSFERRED EXCEPT AS A WHOLE BY THE DEPOSITARY TO A NOMINEE OF THE DEPOSITARY OR BY A NOMINEE OF THE DEPOSITARY TO THE DEPOSITARY OR ANOTHER NOMINEE

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num

Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update – Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 r

Exhibit 99.1 Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update – Enrollment continues in the 2L Phase 3 VERITAC-2 trial and study lead-in for the VERITAC-3 1L Phase 3 trial with vepdegestrant; Top-line data readout for VERITAC-2 remains on-track for 2H 2024 – – Bavdegalutamide mCRPC data presented at ESMO showed median rPFS of 11.1 months in patients with AR 878/87

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Amended and Restated Equity Distribution Agreement, dated November 7, 2023, by and among Arvinas, Inc., Piper Sandler & Co. and Cantor Fitzgerald & Co. (incorporated by reference to Exhibit 1.2 to the Registrant's Registration Statement on Form S-3 (File No. 333-275377) filed with the SEC on November 7, 2023).

Exhibit 1.2 ARVINAS, INC. AMENDED AND RESTATED EQUITY DISTRIBUTION AGREEMENT November 7, 2023 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 CANTOR FITZGERALD & CO. 110 E. 59th St., 6th Floor New York, New York 10028 Ladies and Gentlemen: Arvinas, Inc., a Delaware corporation (the “Company”), and Piper Sandler & Co. and Cantor Fitzgerald & Co. (each, an “Age

AR Franchise Update Bavdegalutamide and ARV-766 October 22, 2023 Exhibit 99.2 Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 199

ex-992xesmo23irpresentat AR Franchise Update Bavdegalutamide and ARV-766 October 22, 2023 Exhibit 99.

Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.1 months rPFS with Bavdegalutamide and Updated Positive Interim Data from Second Generation ARV-766 in mCRPC – Data presented at the European Society for Medical Oncology from the Phase 1/2

ex-991xesmodatareleasefi Potential of Arvinas’ PROTAC® AR Degraders Reinforced by 11.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2023 Arvinas, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 22, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L P

Exhibit 99.1 Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update – Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in for the VERITAC-3 1L Phase 3 trial, both in ER+/HER2- metastatic breast cancer – – Interim data from Phase 1/2 dose escalation and expansion trial with ARV-766

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

First Amendment to Collaboration and License Agreement between Arvinas Operations, Inc. and Bayer AG, dated June 30, 2023

bayerarvinasxamendmentx DocuSign Envelope ID: 3068EFB8-4880-47C5-9C04-FDB1E1D99439 i l I : 5CDF20A 1ADD-4EFA-AEA6-F65D3EE 9750 -1- Exhibit 10.

Sixth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated June 13, 2023

arvinassixthleaseamendme SIXTH AMENDMENT TO LEASE :Wl THIS SIXTH AMENDMENT TO LEASE (the "Agreement") is entered into as of this \:! day of June, 2023 by and between SCIENCE PARK DEVELOPMENT CORPORATION, a Connecticut non stock corporation having its office at 5 Science Park, New Haven, Connecticut 06511 (the "Landlord"), and ARVINAS OPERATIONS, INC.

Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on June 21, 2023).

exhibit31-secondamendeda Exhibit 3.1 SECOND AMENDED AND RESTATED BYLAWS OF ARVINAS, INC. - i - TABLE OF CONTENTS Page ARTICLE I STOCKHOLDERS ............................................................................................1 1.1 Place of Meetings .....................................................................................................1 1.2 Annual Meeting .....................

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Arvinas, Inc. (Exac

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

EXHIBIT 99.1 Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations – 42% of patients with AR ligand bindin

arv-766p1p2disclosurevf EXHIBIT 99.1 Arvinas Announces Interim Data from the ARV-766 Phase 1/2 Dose Escalation and Expansion Trial Showing Promising Signals of Efficacy in Late-line mCRPC, Including in Patients with AR L702H Mutations – 42% of patients with AR ligand binding domain (LBD) mutations achieved PSA50; in patients with AR L702H mutations, 3 of 5 achieved PSA50 – – ARV-766 was well-toler

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

1 June 8, 2023 ARV-766: Phase 1 and interim Phase 2 data Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substa

june2023arv-766disclosur 1 June 8, 2023 ARV-766: Phase 1 and interim Phase 2 data Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential advantages and therapeutic benefits of bavdegalut

Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update –Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestr

Exhibit 99.1 Arvinas Reports First Quarter 2023 Financial Results and Provides Corporate Update –Multiple vepdegestrant (ARV-471) studies enrolling globally, including Phase 1, 2, and 3 studies– – Preliminary data from the Phase 1b combination trial of vepdegestrant + palbociclib suggests potential clinical benefit in a heavily pretreated patient population – NEW HAVEN, Conn., May 5, 2023 – Arvina

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Arvinas, Inc. (Exact

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Arvinas, Inc. (Exa

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arvinas, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per

As filed with the Securities and Exchange Commission on February 24, 2023

As filed with the Securities and Exchange Commission on February 24, 2023 Registration No.

Subsidiaries of the Registrant.

Exhibit 21.1 Name of Subsidiary State of Incorporation Arvinas Operations, Inc. Delaware Arvinas Androgen Receptor, Inc. Delaware Arvinas Estrogen Receptor, Inc. Delaware Arvinas Winchester, Inc. Delaware

Amended and Restated IP Contribution Agreement between Arvinas Operations, Inc. and Oerth Bio LLC f/k/a Protag LLC, effective December 20, 2022 (incorporated by reference to Exhibit 10.34 to the Registrant’s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on February 23, 2023).

CONFIDENTIAL Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential.

Amendment No. 3 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc (formerly Arvinas, Inc.), dated December 21, 2022 (incorporated by reference to Exhibit 10.32 to the Registrant’s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on February 23, 2023)

EX-10.32 2 arvinaspfizzeramendmentno3.htm EX-10.32 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Exhibit 10.32 Amendment No. 3 to Agreement (“Amendment No. 3”) Amendment No. 3 Effective Date: December 21, 2022 Name of

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Arvinas, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-38672 ARVINAS, INC

Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase 2 monotherapy exp

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update – Initiated multiple trials with ARV-471, including a 2L+ Phase 3 trial for patients with metastatic breast cancer – – Presented Phase 2 monotherapy expansion data from the VERITAC trial for the treatment of patients with metastatic or locally advanced ER+/HER2- breast cancer in a late-li

ARVN / ARVINAS HOLDING COMPANY, LLC / Avidity Partners Management LP Passive Investment

SC 13G/A 1 d955690913g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box

ARVN / ARVINAS HOLDING COMPANY, LLC / EcoR1 Capital, LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

ARVN / ARVINAS HOLDING COMPANY, LLC / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv0317-arvinasinc.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Arvinas Inc. Title of Class of Securities: Common Stock CUSIP Number: 04335A105 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Arvinas, Inc. (Ex

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 9, 2023 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numb

J.P. Morgan Healthcare Conference January 11, 2023 Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial

EX-99.1 2 jpmpresentationfinalx01.htm EX-99.1 J.P. Morgan Healthcare Conference January 11, 2023 Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the anticipated timing of our planned clinical t

Arvinas Announces Changes to its Board of Directors

Exhibit 99.1 Arvinas Announces Changes to its Board of Directors NEW HAVEN, Conn., Dec. 16, 2022 (GLOBE NEWSWIRE) - Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that Brad Margus, M.B.A., has stepped down from the company’s Board and Everett Cunningham has been appointed to join. “We are ver

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Arvinas, Inc. (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Arvinas, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 8, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

ARV-471: Phase 2 VERITAC Trial Results San Antonio Breast Cancer Symposium December 8, 2022 Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Ref

sabcsirdeckdecember82022 ARV-471: Phase 2 VERITAC Trial Results San Antonio Breast Cancer Symposium December 8, 2022 Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the including statements regarding the potential for ARV-471 to become a a best-in-class estrogen receptor targeting therapy and the timing of expected future trials of our ARV-471, including any combination studies.

San Antonio Breast Cancer Symposium®, December 6–10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter. Contact them at [email protected] for permission to reprint and/or distribute. ARV-471, a PR

San Antonio Breast Cancer Symposium?, December 6?10, 2022, Presentation GS3-03 This presentation is the intellectual property of the author/presenter.

ARV-471: Phase 2 VERITAC Trial Results November 22, 2022 Exhibit 99.1 Safe harbor and forward-looking statements 2 This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that i

sabcsirdecknov22final ARV-471: Phase 2 VERITAC Trial Results November 22, 2022 Exhibit 99.

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) – ARV-471 continues to show activity in heavily pre-treated patien

Exhibit 99.1 Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC) ? ARV-471 continues to show activity in heavily pre-treated patients with locally advanced or metastatic ER+/HER2- breast cancer ? Median progression free survival of 3.7 months in all patients and 5.7 m

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update – On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling multiple clinical t

Exhibit 99.1 Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update – On track to initiate enrollment of two Phase 3 trials with ARV-471 in patients with first- and second-line metastatic breast cancer – – Enrolling multiple clinical trials and initiating enrollment activity across estrogen receptor (ER) and androgen receptor (AR) franchises – NEW HAVEN, Conn. – Novembe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ý QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Num

First Amendment to Lease between 101 College Street, LLC and Arvinas Operations, Inc., dated August 5, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36874) filed with the SEC on November 9, 2022).

Exhibit 10.1 FIRST AMENDMENT First Amendment (this “First Amendment”), dated as of August 10, 2022 (the “Effective Date”), between 101 COLLEGE STREET, LLC ("Landlord") and ARVINAS OPERATIONS, INC. (“Tenant”). W I T N E S S E T H : WHEREAS, by lease (the "Lease"), dated as of May 4, 2021, between Landlord and Tenant, certain premises (the “Premises”) more particularly described in the Lease, consis

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Arvinas, Inc. (E

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 16, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numb

Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Exhibit 99.1 Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update NEW HAVEN, Conn. ? August 4, 2022 ? Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. ?This is an exciting

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Exhibit 10.1 to the Registrant’s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 4, 2022).

Exhibit 10.1 CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**] HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. MASTER IN VITRO DIAGNOSTICS AGREEMENT between FOUNDATION MEDICINE, INC., ARVINAS OPERATIONS, INC. and, solely for purposes of Section 11.19 hereof, ARVINAS, INC. Dated as of June 4, 2022 Master

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 16, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

ARVN / ARVINAS HOLDING COMPANY, LLC / Avidity Partners Management LP Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.

Entry into a Material Definitive Agreement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 4, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

ARVN / ARVINAS HOLDING COMPANY, LLC / EcoR1 Capital, LLC Passive Investment

SC 13G 1 arvn13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) May 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number:

Form of Restricted Stock Unit Agreement under 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36874) filed with the SEC on May 5, 2022).

Exhibit 10.2 Arvinas, Inc. RESTRICTED STOCK UNIT AGREEMENT Arvinas Inc. (the ?Company?) hereby grants the following restricted stock units pursuant to its 2018 Stock Incentive Plan. The terms and conditions attached hereto are also a part hereof. Notice of Grant Name of recipient (the ?Participant?): Grant Date: Number of Restricted Stock Units (?RSUs?) granted: Number, if any, of RSUs that vest i

Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update

Exhibit 99.1 Arvinas Reports First Quarter 2022 Financial Results and Provides Corporate Update NEW HAVEN, Conn. – May 5, 2022 – Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2022 and provided a corporate update. “It has been a very prod

Amendment No. 2 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated January 14, 2022

Exhibit 10.1 EXECUTION VERSION Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Amendment No. 2 to Agreement (?Amendment No. 2?) Amendment No. 2 Effective Date: January 14, 2022 Name of Original Agreement: Research Collab

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confide

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy S

Subsidiaries of the Registrant.

Exhibit 21.1 Name of Subsidiary State of Incorporation Arvinas Operations, Inc. Delaware Arvinas Androgen Receptor, Inc. Delaware Arvinas Estrogen Receptor, Inc. Delaware Arvinas Winchester, Inc. Delaware

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 28, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

As filed with the Securities and Exchange Commission on February 28, 2022

As filed with the Securities and Exchange Commission on February 28, 2022 Registration No.

Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn. ? February 28, 2022 ? Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a cor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Content UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-3

Calculation of Filing Fee Tables

Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Arvinas, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1?Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock, $0.001 par value per

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the potential advantages and therapeutic

Bavdegalutamide (ARV-110): Phase 1 Dose Escalation and Interim ARDENT Phase 2 Dose Expansion Trial Results February 17, 2022 ASCO Genitourinary Cancers Symposium, 2022 Exhibit 99.

Arvinas PROTAC® Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer – Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (a

Exhibit 99.1 Arvinas PROTAC? Protein Degrader Bavdegalutamide (ARV-110) Continues to Demonstrate Clinical Benefit in Men with Metastatic Castration-Resistant Prostate Cancer ? Bavdegalutamide treatment demonstrated robust activity in molecularly defined tumors (androgen receptor T878X/H875Y), with a 46% PSA50 rate and durable RECIST responses ? ? Data support the potential for an accelerated appro

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2022 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting – Bavdegalutamide demonstrated a 46% PSA50 rat

EX-99.1 Exhibit 99.1 Arvinas Announces New Data from Completed Phase 1 Dose Escalation and Ongoing Phase 2 ARDENT Expansion Cohort with Novel PROTAC® Degrader Bavdegalutamide (ARV-110) to be Presented at 2022 ASCO GU Meeting – Bavdegalutamide demonstrated a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) and androgen receptor (AR) T878X/H875Y tumor mutations

ARVN / ARVINAS HOLDING COMPANY, LLC / New Leaf Ventures III, L.P. - SC 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (Amendment No. 1) Arvinas, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2021 (Date of Event Which Requi

ARVN / ARVINAS HOLDING COMPANY, LLC / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment

SC 13G 1 tv0316-arvinasinc.htm SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Arvinas Inc. Title of Class of Securities: Common Stock CUSIP Number: 04335A105 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Sch

ARVN / ARVINAS HOLDING COMPANY, LLC / Canaan IX L.P. - SC 13G/A Passive Investment

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Arvinas, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

2018 POWER OF ATTORNEY

Exhibit 24 2018 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a ?Grantor?), effective from the date set forth opposite the name of such Grantor on the signature pages hereto (such date

Joint Filing Agreement

EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each

Safe harbor and forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regardi

ARV-471: Phase 1 Dose Escalation Clinical Trial Results San Antonio Breast Cancer Symposium December 10, 2021 Exhibit 99.

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer – ARV-471 continues to show a favorable tolerability profi

Exhibit 99.1 Arvinas and Pfizer Announce PROTAC? Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer ? ARV-471 continues to show a favorable tolerability profile and robust ER degradation in updated phase 1 dose escalation data presented at San Antonio Breast Cancer Symposium ? ? ARV-471 is expe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 ARV

Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Exhibit 99.1 Arvinas Reports Third Quarter 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn. ? November 3, 2021 ? Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. ?The team at Ar

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Num

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File N

Excerpt from Company Presentation, dated September 28, 2021

Rapid pace of anticipated milestones ARV-110 (AR PROTAC?) Initiate abiraterone combination study Share complete Phase 1 dose escalation and interim ARDENT Phase 2 data (anticipated at ASCO GU) Share completed ARDENT Phase 2 data Share interim abiraterone combination data ARV-766 (AR PROTAC?) Initiate Phase 1 Share Phase 1 data Initiate Phase 2 INDs ARV-766 BCL6 Tau Undisclosed oncology ARV-471 (ER

ARVN / ARVINAS HOLDING COMPANY, LLC / PFIZER INC - SC 13G ARVINAS, INC. Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No.)* ARVINAS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04335A105 (CUSIP Number) September 13, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File N

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.001 per share $300,000,000 $32,730

Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251326 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities to be Registered Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Common Stock, par value $0.001 per share $300,000,000 $32,730 (1) Calculated in accordance with Rules 457(o) under the Securities Act of 1933, as amended. This ?Calcu

Equity Distribution Agreement, dated August 6, 2021, by and among Arvinas, Inc., Piper Sandler & Co. and Cantor Fitzgerald & Co.

Exhibit 1.1 Execution Version ARVINAS, INC. EQUITY DISTRIBUTION AGREEMENT August 6, 2021 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 CANTOR FITZGERALD & CO. 499 Park Avenue New York, New York 10022 Ladies and Gentlemen: As further set forth in this agreement (this ?Agreement?), Arvinas, Inc., a Delaware corporation (the ?Company?), proposes to issue and s

Common Stock

Filed Pursuant to Rule 424(b)(5) Registration No. 333-234035 PROSPECTUS SUPPLEMENT (To Prospectus Dated October 10, 2019) Common Stock This prospectus supplement supplements the equity distribution agreement prospectus dated October 10, 2019 related to the offer and sale of shares of our common stock, $0.001 par value per share, pursuant to an equity distribution agreement, or the Equity Distribut

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

Lease between 101 College Street, LLC and Arvinas Operations, Inc., dated May 4, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-36874) filed with the SEC on August 5, 2021).

EXHIBIT 10.1 LEASE 101 College STREET, LLC (LANDLORD) AND arvinas OPERATIONS, INC. (TENANT) DATED: AS OF May 4, 2021 EAST\174041517.9 Table of Contents Page ARTICLE 1 DEFINITIONS 1 ARTICLE 2 DEMISE; PREMISES; TERM 2 ARTICLE 3 OCCUPANCY OF THE PREMISES, LANDLORD?S WORK AND FINISH WORK 4 ARTICLE 4 RENT 4 ARTICLE 5 USE 5 ARTICLE 6 ADDITIONAL RENT 6 ARTICLE 7 INSURANCE 12 ARTICLE 8 COMPLIANCE WITH LAW

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numbe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 ARVINAS,

Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update

Exhibit 99.1 Arvinas Reports Second Quarter 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn. ? August 5, 2021 ? Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2021 and provided a corporate update. ?Arvinas has made tr

Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC® Protein Degrader ARV-471 – Collaboration combines Arvinas’ investigational estrogen receptor-targeting breast cancer therapy with Pfizer’s deep experience in breast

Exhibit 99.1 Arvinas and Pfizer Announce Global Collaboration to Develop and Commercialize PROTAC? Protein Degrader ARV-471 ? Collaboration combines Arvinas? investigational estrogen receptor-targeting breast cancer therapy with Pfizer?s deep experience in breast oncology therapeutics ? ? ARV-471 is currently in Phase 2 development for the treatment of patients with locally advanced or metastatic

We are Progressing our Pipeline of Validated and “Undruggable” Targets in Oncology, Immuno-oncology, and Neuroscience †Denotes historically undruggable proteins Note: Pipeline is non-exhaustive and IND dates are anticipated. mCRPC, metastatic castrat

ARV-471: Robust Development Plans with Multiple Milestones CDK, cyclin-dependent kinase; SABCS, San Antonio Breast Cancer Symposium 2022+ 2H 2021 Complete Phase 1 dose escalation data (anticipated at SABCS) Initiate Phase 1b combination study with everolimus Begin Phase 2 study in early breast cancer (neoadjuvant setting) VERITAC Phase 2 data Phase 1b IBRANCE? (palbociclib) combination study data Phase 1b everolimus combination study data Ph 3 studies across multiple lines of therapy (+/- CDK4/6 inhibitor) Pivotal early BC program Umbrella study to explore multiple combination agents Exhibit 99.

Investor Agreement, dated July 21, 2021, by and between Arvinas, Inc. and Pfizer, Inc.

Exhibit 10.3 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. Execution Version INVESTOR AGREEMENT By and Between PFIZER INC. AND ARVINAS, INC. Dated as of July 21, 2021 TABLE OF CONTENTS 1. Definitions 1 2. Standstill 3

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Results of Operations and Financial Condition, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

Stock Purchase Agreement, dated July 21, 2021, by and between Arvinas, Inc. and Pfizer, Inc.

Exhibit 10.2 Execution Version STOCK PURCHASE AGREEMENT By and Between PFIZER INC. AND ARVINAS, INC. Dated as of July 21, 2021 TABLE OF CONTENTS Page 1.???Definitions. 1 1.1??Defined Terms 1 2.???Purchase and Sale of Common Stock 6 2.1??Closing 6 2.2??Number of Shares 6 3.???Closing Date; Deliveries 6 3.1??Closing Date 6 3.2??Deliveries 6 4.???Representations and Warranties of the Company 7 4.1??O

Collaboration Agreement, dated July 21, 2021, by and between Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer, Inc.

Exhibit 10.1 Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type of information that the registrant treats as private or confidential. Double asterisks denote omissions. COLLABORATION AGREEMENT BY AND AMONG ARVINAS, INC., ARVINAS OPERATIONS, INC., ARVINAS ESTROGEN RECEPTOR, INC. AND PFIZER INC. DATED AS OF JULY 21, 2021 TABLE O

Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2021 ARVINAS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-38672 47-2566120 (State or Other Jurisdiction of Incorporation (Commission File Number)

Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update

Exhibit 99.1 Arvinas Reports First Quarter 2021 Financial Results and Provides Corporate Update NEW HAVEN, Conn., May 4, 2021 ? Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the first quarter ended March 31, 2021 and provided a corporate update. ?Last quarter we rein

Quarterly Report - 10-Q

f UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38672 ARVIN

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number)

- 2021 DEFA14A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

definitive proxy statement

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Number

Subsidiaries of the Registrant.

Exhibit 21.1 Name of Subsidiary State of Incorporation Arvinas Operations, Inc. Delaware Arvinas Androgen Receptor, Inc. Delaware Arvinas Estrogen Receptor, Inc. Delaware Arvinas Winchester, Inc. Delaware

- S-8

As filed with the Securities and Exchange Commission on March 1, 2021 Registration No.

Annual Report - 10-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO . Commission File Number: 001-38672 ARVINAS, INC

Audited Financial Statements of Oerth Bio, LLC, as of December 31, 2020.

Exhibit 99.1 Oerth Bio, LLC Financial Statements as of December 31, 2020 and 2019, and for the Year Ended December 31, 2020 and the Period from May 24, 2019 (Date of Formation) to December 31, 2019, and Independent Auditors? Report OERTH BIO, LLC table of contents Page INDEPENDENT AUDITORS? REPORT 1 FINANCIAL STATEMENTS AS OF DECEMBER 31, 2020 AND 2019, AND FOR THE YEAR ENDED DECEMBER 31, 2020 AND

Second Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 4, 2021 (incorporated by reference to Exhibit 10.35 to the Registrant's Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 1, 2021).

Exhibit 10.35 SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (the ?Agreement?) is entered into as of this 4th day of January, 2021 by and between SCIENCE PARK DEVELOPMENT CORPORATION, a Connecticut non stock corporation having its office at 5 Science Park, New Haven, Connecticut 06511 (the ?Landlord?), and ARVINAS OPERATIONS, INC., f/k/a Arvinas, Inc., a Delaware corporation having a pri

Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

Exhibit 99.1 Arvinas Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update NEW HAVEN, Conn., March 1, 2021 ? Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradation, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided a corp

Fifth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 4, 2021 (incorporated by reference to Exhibit 10.34 to the Registrant's Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 1, 2021).

Exhibit 10.34 FIFTH AMENDMENT TO LEASE THIS FIFTH AMENDMENT TO LEASE (the ?Agreement?) is entered into as of this 4th day of January, 2021 by and between SCIENCE PARK DEVELOPMENT CORPORATION, a Connecticut non stock corporation having its office at 5 Science Park, New Haven, Connecticut 06511 (the ?Landlord?), and ARVINAS OPERATIONS, INC., f/k/a Arvinas, Inc., a Delaware corporation having a princ

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Arvinas, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARVINAS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARVINAS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04335A105 (CUSIP Number) January 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursu

Joint Filing Agreement

EX-99.1 EXHIBIT 99.1 Joint Filing Agreement The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing statements. The undersigned acknowledge that each

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Arvinas, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities)

SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Arvinas, Inc. (Name of Issuer) COMMON STOCK, $0.001 PAR VALUE PER SHARE (Title of Class of Securities) 04335A105 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th

2018 POWER OF ATTORNEY

EX-24 2 d111909dex24.htm EX-24 Exhibit 24 2018 POWER OF ATTORNEY 1. Appointment, Powers and Revocation. KNOW ALL MEN BY THESE PRESENTS, that each undersigned, and if such undersigned is not a natural person, acting by and through one of its authorized representatives (each such undersigned person or entity, a “Grantor”), effective from the date set forth opposite the name of such Grantor on the si

Entry into a Material Definitive Agreement - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 4, 2021 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Numb

Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock

EX-99.1 Exhibit 99.1 Arvinas, Inc. Announces Pricing of $400 Million Public Offering of Common Stock NEW HAVEN, Conn., December 15, 2020 – Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC® Discovery Engine, today announced the pricing of an underwritten public offering of 5,714,286 shares of it

Underwriting Agreement, dated December 15, 2020, by and among Arvinas, Inc. and Goldman Sachs & Co. LLC and Piper Sandler & Co., as representatives of the underwriters named therein

EX-1.1 Exhibit 1.1 Arvinas, Inc. Common Stock Underwriting Agreement December 15, 2020 Goldman Sachs & Co. LLC Piper Sandler & Co. As representatives of the several Underwriters named in Schedule I hereto c/o Goldman Sachs & Co. LLC 200 West Street, New York, New York 10282 c/o Piper Sandler & Co. 800 Nicolette Mall Minneapolis, Minnesota 55402 Ladies and Gentlemen: Arvinas, Inc., a Delaware corpo

Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events - 8-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2020 Arvinas, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38672 47-2566120 (State or other jurisdiction of incorporation) (Commission File Nu

CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.001 per share 6,571,428

424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-251326 CALCULATION OF REGISTRATION FEE Title of Each Class of Securities Offered Amount to be Registered(1) Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.001 per share 6,571,428 $ 70.00 $ 459,999,960.00 $ 50,186.00 (1) Assumes exercise in full

Safe harbor and forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regardi

EX-99.2 Clinical Program Update: ARV-471 & ARV-110 14 December 2020 Exhibit 99.2 Safe harbor and forward-looking statements This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the development and regulatory status of our product candidates, s